{"nctId":"NCT01402115","briefTitle":"A 12-week Human Trial to Compare the Efficacy and Safety of Polycan on Bone Metabolism","startDateStruct":{"date":"2008-11"},"conditions":["Bone Health in Perimenopausal Women"],"count":60,"armGroups":[{"label":"Polycan","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Polycan"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"name":"Polycan","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* They were required to have reduced bone density but no evidence of osteoporosis or osteopenia by Dual-emission X-ray absorptiometry (DEXA) scan (T â‰¥ -1.0 in the lumbar spine).\n* Perimenopausal women : aged 40-70\n\nExclusion Criteria:\n\n* Women with a body mass index (BMI) \\>30 kg/m2 or who were being treated with estrogens, corticosteroids, or bisphosphonates, or who had significant illness affecting bone metabolism were excluded","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"40 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in DPD(Deoxypyridinoline)","description":"DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"2.2"},{"groupId":"OG001","value":"6.4","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"2.1"},{"groupId":"OG001","value":"5.6","spread":"1.5"}]}]}]},{"type":"PRIMARY","title":"Changes in OSC(Osteocalcin)","description":"OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"6.8"},{"groupId":"OG001","value":"14.2","spread":"5.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":"7.7"},{"groupId":"OG001","value":"17.0","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Changes in CTx(Collagen Type 1 Cross-linked C-telopeptide)","description":"CTx(collagen type 1 cross-linked C-telopeptide) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":"183"},{"groupId":"OG001","value":"314","spread":"217"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":"171"},{"groupId":"OG001","value":"301","spread":"157"}]}]}]},{"type":"SECONDARY","title":"Changes in bALP(Bone-specific Alkaline Phosphatase)","description":"bALP(bone-specific alkaline phosphatase) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":"11.3"},{"groupId":"OG001","value":"28.6","spread":"9.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":"11.7"},{"groupId":"OG001","value":"29.8","spread":"9.5"}]}]}]},{"type":"SECONDARY","title":"Changes in PTH(Parathyroid Hormone)","description":"PTH(parathyroid hormone) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":"10.4"},{"groupId":"OG001","value":"31.1","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"9.3"},{"groupId":"OG001","value":"33.6","spread":"7.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":[]}}}